One morning, you wake up, and straight lines appear wavy; your favorite book looks blurred in the center, and you find yourself unable even to recognize the faces of your loved ones. These sudden changes terrify you because wet AMD can damage your vision within weeks or even days if left untreated.
The good news is that Pavblu and Eylea are equally effective in treating wet AMD. Both medications contain the same active ingredient, aflibercept, and clinical trials show they deliver identical results. This means you have options that can stop your vision loss and help you return to your daily activities.
What Is Wet AMD?
Wet AMD is a severe eye disease that impairs central vision. It occurs when abnormal blood vessels grow beneath the retina and begin leaking fluid or blood. This leakage damages the macula, the part of your eye that processes detailed vision.
Wet AMD is associated with sudden vision problems. There is a blurred spot in the central portion of the visual field. Straight lines appear wavy or crooked, and colors are harder to distinguish, especially blue and yellow. This type accounts for only 10-15% of AMD cases but leads to the most severe vision losses.
Understanding Pavblu and Eylea
Eylea is the original brand-name drug containing aflibercept. It was approved by the FDA for wet AMD in 2011. Pavblu is a biosimilar version of Eylea, which therefore includes the same active ingredient with a highly similar structure and function.
Both medications work by the exact mechanism. They serve as decoy receptors that block vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), which are responsible for abnormal blood vessel growth in wet AMD patients. By blocking these proteins, both drugs stop the growth of leaky vessels and reduce swelling.
Clinical Trial Results: Pavblu versus Eylea
In a major clinical study involving 579 adults with wet AMD, Pavblu was directly compared with Eylea. The results showed complete equivalence between the treatments: patients in both groups improved by about 6.5 letters on standard eye tests after 8 weeks of treatment.
The FDA approval study enrolled 566 patients across 126 global sites. Patients were randomized to either Pavblu or Eylea. Laboratory tests demonstrated that Pavblu produces the same amount of active substance in the body as Eylea.
Long-term data show sustained benefits. At week 52, both medications maintained their effectiveness with no clinically meaningful differences in safety, efficacy, or immunogenicity. Eylea clinical trials demonstrate that 95% of patients with wet AMD maintained vision for 52 weeks.
Safety Profile Comparison
Both Pavblu and Eylea have the same safety profile. Regulatory agencies reviewed extensive data and found no significant differences in adverse events between the two drugs. Common adverse events occur similarly for both medications.
The CHMP concluded that Pavblu’s benefits are similar to those of Eylea and that its risks are comparable. Contraindications to their use include patients with eye infections or severe intraocular inflammation. The safety measures for both treatments will be identical and must be carried out by healthcare providers.
Dosing Schedule for Wet AMD
Pavblu and Eylea are administered on the same dosing schedule in the treatment of wet AMD. Patients receive 2 mg injections every 4 weeks for the first 3 months. After the initial phase, dosing is extended to every 8 weeks.
Both medications are administered by intravitreal injection; the drugs are directly injected into the eye. Some patients will require more frequent dosing, although most studies have shown that no additional benefit is gained with injections every 4 weeks compared to every 8 weeks.
Cost and Accessibility Factors
Pavblu came into the market as a biosimilar to make Eylea more accessible. Generally, biosimilars are cheaper than brand-name drugs while maintaining the same therapeutic effect. The FDA approved Pavblu in September 2024 for the treatment of wet AMD and other retinal conditions.
Several biosimilars are on the market competing with aflibercept, including Pavblu and Enzeevu. This may enhance patients’ access to treatment by reducing costs and increasing supply.
Take Control of Your Vision Today
Pavblu and Eylea are therapeutically equivalent in treating wet AMD. Clinical evidence shows they deliver the same efficacy, safety, and outcomes in this area. Your choice may depend on factors like insurance coverage, cost, and availability rather than effectiveness differences.
Both drugs preserve vision in the overwhelming majority of patients when administered on schedule. Regulatory bodies in the United States, Europe, and Canada have all concluded that Pavblu is interchangeable with Eylea for all clinically meaningful parameters.
Wet AMD can rob you of your vision and independence. Every day you wait, you put your eyesight at greater risk. Schedule an appointment today with a retina specialist to determine if Pavblu or Eylea is right for you. The earlier you act, the more likely you are to save your sight and be able to continue doing the things you love.
Need expert guidance on wet AMD treatment options? RVAF connects you with the necessary eye care professional experience, enabling you to make treatment decisions with confidence.